A positive relationship between MDM2 inhibition and the inhibition of the phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR)/E-twenty six proto-oncogene 2 (ETS2) pathway was identified in PC3 prostate cancer cells [70]. Here, MTOR is linked to prostate carcinoma.